Novavax Inc (NVAX)
$129.00
0.98 (0.75%)
NVAX Stock Quote Delayed 30 Minutes
Previous Close
-
Market Cap
49.24B
PE Ratio
-211.48
EPS
-0.61
Volume (Avg. Vol.)
2.45M
Day's Range
127.91 - 135.71
52-Week Range
4.26 - 189.40
Dividend & Yield
N/A (N/A)
NVAX Stock Predictions, Articles, and Novavax Inc News
Novavax Will Likely Do Well Once Its Covid-19 Vaccine Trials Come Out
NVAX stock is poised for returns once its Phase 3 trial results come out, but potential investors should keep their eyes on the news.
Why Novavax Stock Is Bound for Massive Gains in 2021
Novavax lost the race to be first with a Covid-19 vaccine, but NVX-CoV2373 is nearing approval. It will boost NVAX stock in 2021.
NVAX Stock Is Worth a Small Position but Vaccine Race Is Tightening
Phase 3 trial delays are pushing NVAX stock down, but the biotech still has a reliable vaccine candidate expected to generate $3.9 billion.
Under-the-Radar Novavax Can Still Make a Splash
As Covid-19 vaccine leaders took the headlines, NVAX stock slipped into the shadows. However, the former group’s setbacks could spell upside opportunity for the latter.
Novavax Is Inching Closer, But Its Vaccine Better Be Special
Novavax is trailing the competition in the coronavirus vaccine race, but markets may be punishing NVAX stock too much.
This Drop in Novavax Stock Means Nothing in Context of the Wider View
NVAX stock has settled into a trading range. Wait for the resolution of these levels, then pounce with a trade.
Don’t Let the Vaccine Trial Delay Stop You from Believing in Novavax
If you're concerned over a regulatory bump in the road, relax, as Novavax stock should still have catalysts to drive the share price higher.
Novavax Can Still Make Coronavirus Vaccines Great Again
While Pfizer and Moderna enjoy first-to-market advantage, the reality is that being first in a vaccine race isn’t always the best. Plus, Novavax’s distinct approach could make NVAX stock a strong dark horse.
The Vaccine Race Is Far From Over, And That’s Good News for Novavax
Bill Gates expects Novavax’s vaccine to be effective against Covid-19. Despite Pfizer being first, NVAX stock is still bound to benefit.
The Cusp of an Amazing Technological Revolution
We’re again at the cusp of an amazing technological revolution that will carry the stock market to incredible new highs. Make sure to position yourself to take advantage of this huge profit potential.
Novavax Stock Leads the Board on Wall Street but Lags on Main Street
NVAX stock is up over 3,000% this year yet it's not the one with the doses on the streets. Best to trade the stock while they chase the headline.
Novavax Stock Is an Underdog You Should Bank On
The development a Covid-19 vaccine is no longer a race to the finish line, but there are still plenty of reasons to buy NVAX stock.
Don’t Be Surprised, Novavax Stock Is on the Rise Again
Novavax is up more than 33% in the last month, and at least one analyst believes NVAX stock has more than an 80% upside.
Novavax Far From Finished In the Race for a Vaccine
Four of six analysts call NVAX stock a buy. From where I sit, they’re spot on. Consider that in the first quarter of 2021, they expect the company to report a profit of $3.89 per share. I mean, wow.
Take Advantage of Investor Impatience with Novavax
NVAX stock has faltered lately, as other companies seem to have taken the lead in the Covid-19 vaccine race. But patience will be rewarded.
Novavax Stock a Strong Bet to Ride the Vaccination Wave
Novavax is in Phase 3 trials with its novel coronavirus vaccine and success there will provide massive momentum for NVAX stock.
Hold on to Your Novavax Stock and Don’t Fear the Competition
It's tricky to pick a winner in the Covid vaccine race, but NVAX stock traders should know that there's room for more than one success story.
Navellier Ratings
Powered by Portfolio GraderTotal Grade
B
